Test Code CSMHP Controlled Substance Monitoring Hybrid Plus Drug Profile, 19 Drug Classes, High-Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine
Ordering Guidance
This test does not screen for drug classes other than those listed in Reference Values.
Specimen Required
Supplies: Urine Container, 60 mL (T313)
Collection Container/Tube: Plastic urine container
Submission Container/Tube: Plastic, 60-mL urine container
Specimen Volume: 30 mL
Collection Instructions:
1. Collect a random urine specimen.
2. Submit 30 mL in 1 plastic bottle.
3. No preservative.
Additional Information:
1. No specimen substitutions.
2. Submitting less than 30 mL may compromise the ability to perform all necessary testing.
3. STAT requests are not accepted for this test.
Forms
If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:
-Therapeutics Test Request (T831)
Useful For
Detecting drug use involving stimulants, benzodiazepines, cocaine, opioids, and gabapentinoids.
Clinical monitoring or management of patients
This test is not intended for use in employment-related testing.
Profile Information
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| LPCM | List Patient's Current Medications | No | Yes |
| ADULT | Adulterants Survey, U | Yes | Yes |
| SCOCA | Cocaine IA Screen, U | No | Yes |
| TOPU | Targeted Opioid MS Screen, U | Yes, (Order TOSU) | Yes |
| TABSU | Targeted Benzodiazepine Screen, U | Yes, (Order TBSU) | Yes |
| TSIM | Gabapentinoid/Stim MS Screen, U | Yes, (Order TGSU) | Yes |
Testing Algorithm
Testing begins with an adulterant survey. If the sample is found to be adulterated, testing will end and the remaining tests will be canceled.
If the specimen is normal or only diluted, remaining testing will continue.
Positive results can be confirmed and quantitated by gas chromatography mass spectrometry for cocaine and metabolites at an additional charge.
Special Instructions
Method Name
ADULT: Spectrophotometry (SP)
SCOCA: Immunoassay
TABSU, TOPU, TSIM: Liquid Chromatography Tandem Mass Spectrometry, High-Resolution Accurate Mass (LC-MS/MS HRAM)
Reporting Name
CSM Hybrid Plus,19, HRMS/IA, USpecimen Type
UrineSpecimen Minimum Volume
20 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Urine | Refrigerated (preferred) | 14 days |
| Frozen | 14 days |
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Clinical Information
The cocaine screen portion uses immunoassay screening techniques. A positive immunoassay screening result can be confirmed by gas chromatography mass spectrometry and quantitated at an additional charge.
The targeted opioid, benzodiazepine, and stimulant screen portions are performed using liquid chromatography tandem mass spectrometry, high-resolution accurate mass and are completed for all opioids, benzodiazepines, and stimulants. Opioids are a large class of medications commonly used to relieve acute and chronic pain or help manage opioid abuse and dependence. Medications that fall into this class include buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone, tapentadol, tramadol, and others. Opioids work by binding to the opioid receptors that are found in the brain, spinal cord, gastrointestinal tract, and other organs. Common side effects for opioids include drowsiness, confusion, nausea, constipation, and, in severe cases, respiratory depression. These are dose dependent and vary with tolerance. These medications can also produce physical and psychological dependence and have a high risk for abuse and diversion, which is one of the main reasons many professional practice guidelines recommend compliance testing in patients prescribed these medications.
Opioids are readily absorbed from the gastrointestinal tract, nasal mucosa, lungs, and after subcutaneous or intermuscular injection. Opioids are primarily excreted from the kidney in both free and conjugated forms. This assay does not hydrolyze the urine sample and looks for both parent drugs and metabolites (including glucuronide forms). The detection window for most opioids in urine is approximately 1 to 3 days with longer detection times for some compounds (ie, methadone).
Benzodiazepines represent a large family of medications used to treat a wide range of disorders from anxiety to seizures and are also used in pain management. With a high risk for abuse and diversion, professional practice guidelines recommend compliance monitoring for these medications using urine drug tests. However, traditional benzodiazepine immunoassays suffer from a lack of cross-reactivity with all the benzodiazepines, so many compliant patients taking either clonazepam (Klonopin) or lorazepam (Ativan) may screen negative by immunoassay but are positive when confirmatory testing is done. The new targeted benzodiazepine screening test provides a more sensitive and specific test to check for compliance to all the commonly prescribed benzodiazepines and looks for both parent drugs and metabolites in the urine.
Stimulants are sympathomimetic amines that stimulate the central nervous system activity and, in part, suppress the appetite. Amphetamine and methamphetamine are also prescription drugs used in the treatment of narcolepsy and attention-deficit disorder/attention-deficit hyperactivity disorder (ADHD). Methylphenidate is another stimulant used to treat ADHD. Phentermine is indicated for the management of obesity. All other amphetamines (eg, methylenedioxymethamphetamine: MDMA) are Drug Enforcement Administration-scheduled Class I compounds. Due to their stimulant effects, the drugs are commonly sold illicitly and abused. Physiological symptoms associated with very high amounts of ingested amphetamine or methamphetamine include elevated blood pressure, dilated pupils, hyperthermia, convulsions, and acute amphetamine psychosis.
Gabapentinoids (pregabalin, gabapentin) are widely used in neurology, psychiatry, and primary care, with increasing reports of misuse. They decrease central neuronal excitability by binding to the calcium channel of hyperexcited neurons which results in a reduction in the release of excitatory molecules including glutamate and noradrenaline. Gabapentin is not metabolized or protein bound and is primarily excreted and detectable in the urine for up to four days. Pregabalin is also largely excreted unchanged in the urine and detectable for up to 6 days.
This test is intended to be used in a setting where the test results can be used to make a definitive diagnosis.
Reference Values
ADULTERANT SURVEY:
Cutoff concentrations
Oxidants: 200 mg/L
Nitrites: 500 mg/L
COCAINE IMMUNOASSAY SCREEN:
Negative
Screening cutoff concentrations:
Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL
TARGETED OPIOID MASS SPECTROMETRY SCREEN:
Not detected (Positive results are reported with qualitative "Present" results)
Cutoff concentrations:
Codeine: 25 ng/mL
Codeine-6-beta-glucuronide: 100 ng/mL
Morphine: 25 ng/mL
Morphine-6-beta-glucuronide: 100 ng/mL
6-Monoacetylmorphine: 25 ng/mL
Hydrocodone: 25 ng/mL
Norhydrocodone: 25 ng/mL
Dihydrocodeine: 25 ng/mL
Hydromorphone: 25 ng/mL
Hydromorphone-3-beta-glucuronide: 100 ng/mL
Oxycodone: 25 ng/mL
Noroxycodone: 25 ng/mL
Oxymorphone: 25 ng/mL
Oxymorphone-3-beta-glucuronide: 100 ng/mL
Noroxymorphone: 25 ng/mL
Fentanyl: 2 ng/mL
Norfentanyl: 2 ng/mL
Meperidine: 25 ng/mL
Normeperidine: 25 ng/mL
Naloxone: 25 ng/mL
Naloxone-3-beta-glucuronide: 100 ng/mL
Methadone: 25 ng/mL
2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP): 25 ng/mL
Tramadol: 25 ng/mL
O-desmethyltramadol: 25 ng/mL
Tapentadol: 25 ng/mL
N-desmethyltapentadol: 50 ng/mL
Tapentadol-beta-glucuronide: 100 ng/mL
Buprenorphine: 5 ng/mL
Norbuprenorphine: 5 ng/mL
Norbuprenorphine glucuronide: 20 ng/mL
TARGETED BENZODIAZEPINE MASS SPECTROMETRY SCREEN:
Not detected (Positive results are reported with qualitative "Present" results)
Cutoff concentrations:
Alprazolam: 10 ng/mL
Alpha-hydroxyalprazolam: 10 ng/mL
Alpha-hydroxyalprazolam glucuronide: 50 ng/mL
Chlordiazepoxide: 10 ng/mL
Clobazam: 10 ng/mL
N-desmethylclobazam: 200 ng/mL
Clonazepam: 10 ng/mL
7-Aminoclonazepam: 10 ng/mL
Diazepam: 10 ng/mL
Nordiazepam: 10 ng/mL
Flunitrazepam: 10 ng/mL
7-Aminoflunitrazepam: 10 ng/mL
Flurazepam: 10 ng/mL
2-Hydroxy ethyl flurazepam: 10 ng/mL
Lorazepam: 10 ng/mL
Lorazepam glucuronide: 50 ng/mL
Midazolam: 10 ng/mL
Alpha-hydroxymidazolam: 10 ng/mL
Oxazepam: 10 ng/mL
Oxazepam glucuronide: 50 ng/mL
Prazepam: 10 ng/mL
Temazepam: 10 ng/mL
Temazepam glucuronide: 50 ng/mL
Triazolam: 10 ng/mL
Alpha-hydroxytriazolam: 10 ng/mL
Zolpidem: 10 ng/mL
Zolpidem phenyl-4-carboxylic acid: 10 ng/mL
TARGETED GABAPENTINOID AND STIMULANT MASS SPECTROMETRY SCREEN:
Not detected (Positive results are reported with qualitative "Present" results)
Cutoff concentrations:
Methamphetamine: 100 ng/mL
Amphetamine: 100 ng/mL
3,4-Methylenedioxymethamphetamine (MDMA): 100 ng/mL
3,4-Methylenedioxy-N-ethylamphetamine (MDEA): 100 ng/mL
3,4-Methylenedioxyamphetamine (MDA): 100 ng/mL
Ephedrine: 100 ng/mL
Pseudoephedrine: 100 ng/mL
Phentermine: 100 ng/mL
Phencyclidine (PCP): 20 ng/mL
Methylphenidate: 20 ng/mL
Ritalinic acid: 100 ng/mL
Gabapentin: 500 ng/mL
Pregabalin: 500 ng/mL
Interpretation
A positive result derived by this testing indicates that the patient has used one of the drugs detected by these techniques in the recent past.
For information about drug testing, including estimated detection times and Result Interpretations, see Controlled Substance Monitoring on MayoClinicLabs.com.
Cautions
It is possible that substances other than those investigated in the specificity study may interfere with the test and cause false-positive or false-negative results.
Method Description
Adulterant:
All results are measured using spectrophotometry at wavelengths specified by the reagent manufacturer. The use of a refractometer may also be used in the specific gravity measurement.(Package inserts: Specimen Validity Test Creatinine. Roche Diagnostics; V3.0, 05/2023; Specimen Validity Test Nitrite. Roche Diagnostics; V2.0, 05/2022; Specimen Validity Test Oxidant. Roche Diagnostics; V2.0, 05/2022; Specimen Validity Test pH Roche Diagnostics; V2.0, 05/2022, Specimen Validity Test Specific Gravity. Roche Diagnostics; V3.0, 08/2022)
Cocaine screen:
The cocaine metabolite assay is on the kinetic interaction of microparticles in a solution as measured by changes in light transmission. In the absence of sample drug, soluble drug conjugates bind to antibody-bound microparticles, causing the formation of particle aggregates. As the aggregation reaction proceeds in the absence of sample drug, the absorbance increases. When a urine sample contains the drug in question, this drug competes with the drug derivative conjugate for microparticle-bound antibody. Antibody bound to sample drug is no longer available to promote particle aggregation, and subsequent particle lattice formation is inhibited. The presence of sample drug diminishes the increasing absorbance in proportion to the concentration of drug in the sample. Sample drug content is determined relative to the value obtained for a known cutoff concentration of drug.(Package inserts: COC2. Roche Diagnostics; V4.0, 04/2024)
Opioid, benzodiazepine, and gabapentinoid/stimulant targeted screening panels:
The urine sample is diluted with internal standard and clinical laboratory reagent water and then analyzed by liquid chromatography tandem mass spectrometry using a high-resolution accurate mass orbitrap detector.(Unpublished Mayo method)
Day(s) Performed
Monday through Saturday
Report Available
3 to 4 daysSpecimen Retention Time
14 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
80307
G0482
80326 (if appropriate for select payers)
80347 (if appropriate for select payers)
80364 (if appropriate for select payers)
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| CSMHP | CSM Hybrid Plus,19, HRMS/IA, U | 69739-1 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| LPCM | List Patient's Current Medications | 66423-5 |
| 624198 | Methamphetamine | 19554-5 |
| 20606 | Creatinine, U | 2161-8 |
| 604871 | Alprazolam | 94116-1 |
| 624246 | Cocaine | 19359-9 |
| 624213 | Codeine | 19411-8 |
| 624214 | Codeine-6-beta-glucuronide | 89310-7 |
| 604867 | Alpha-Hydroxyalprazolam | 19325-0 |
| 22312 | Specific Gravity | 5810-7 |
| 624199 | Amphetamine | 19343-3 |
| 624200 | 3,4-methylenedioxymethamphetamine (MDMA) | 19568-5 |
| 23509 | pH | 2756-5 |
| 604891 | Alpha-Hydroxyalprazolam Glucuronide | 94115-3 |
| 624215 | Morphine | 19597-4 |
| 624216 | Morphine-6-beta-glucuronide | 89308-1 |
| 604872 | Chlordiazepoxide | 19385-4 |
| 23511 | Oxidants | 58714-7 |
| 624201 | 3,4-methylenedioxy-N-ethylamphetamine (MDEA) | 59844-1 |
| 624202 | 3,4-methylenedioxyamphetamine (MDA) | 19565-1 |
| 23510 | Nitrites | 32710-6 |
| 604889 | Clobazam | 94114-6 |
| 624217 | 6-monoacetylmorphine | 19321-9 |
| 624218 | Hydrocodone | 19482-9 |
| 604890 | N-Desmethylclobazam | 94113-8 |
| 30914 | Comment | 48767-8 |
| 624203 | Ephedrine | 99108-3 |
| 624204 | Pseudoephedrine | 99109-1 |
| 604873 | Clonazepam | 19399-5 |
| 624219 | Norhydrocodone | 89304-0 |
| 624220 | Dihydrocodeine | 19446-4 |
| 604267 | 7-aminoclonazepam | 94112-0 |
| 624205 | Phentermine | 19674-1 |
| 624206 | Phencyclidine (PCP) | 19659-2 |
| 604874 | Diazepam | 19443-1 |
| 624221 | Hydromorphone | 19486-0 |
| 624222 | Hydromorphone-3-beta-glucuronide | 89309-9 |
| 604880 | Nordiazepam | 19624-6 |
| 624207 | Methylphenidate | 19577-6 |
| 624208 | Ritalinic acid | 99110-9 |
| 604875 | Flunitrazepam | 19466-2 |
| 624223 | Oxycodone | 19642-8 |
| 624224 | Noroxycodone | 89303-2 |
| 604866 | 7-aminoflunitrazepam | 94111-2 |
| 624209 | Gabapentin | 68439-9 |
| 624210 | Pregabalin | 105953-4 |
| 604876 | Flurazepam | 19474-6 |
| 624225 | Oxymorphone | 19646-9 |
| 624226 | Oxymorphone-3-beta-glucuronide | 89301-6 |
| 604868 | 2-Hydroxy Ethyl Flurazepam | 94110-4 |
| 624211 | Stimulant Interpretation | 54247-2 |
| 604877 | Lorazepam | 19520-6 |
| 624227 | Noroxymorphone | 89302-4 |
| 624228 | Fentanyl | 59673-4 |
| 604878 | Lorazepam Glucuronide | 94109-6 |
| 604879 | Midazolam | 19585-9 |
| 624229 | Norfentanyl | 43199-9 |
| 624230 | Meperidine | 19532-1 |
| 604869 | Alpha-Hydroxy Midazolam | 94108-8 |
| 604881 | Oxazepam | 19638-6 |
| 624231 | Normeperidine | 27920-8 |
| 624232 | Naloxone | 42618-9 |
| 604882 | Oxazepam Glucuronide | 94107-0 |
| 604883 | Prazepam | 19678-2 |
| 624233 | Naloxone-3-beta-glucuronide | 89307-3 |
| 624234 | Methadone | 19550-3 |
| 604884 | Temazepam | 19698-0 |
| 604885 | Temazepam Glucuronide | 94106-2 |
| 624235 | EDDP | 93495-0 |
| 624236 | Tramadol | 19710-3 |
| 604886 | Triazolam | 19714-5 |
| 604870 | Alpha-Hydroxy Triazolam | 94105-4 |
| 624237 | O-desmethyltramadol | 86453-8 |
| 624238 | Tapentadol | 72485-6 |
| 604887 | Zolpidem | 94104-7 |
| 604888 | Zolpidem Phenyl-4-Carboxylic acid | 94103-9 |
| 624239 | N-desmethyltapentadol | 89306-5 |
| 624240 | Tapentadol-beta-glucuronide | 89300-8 |
| 604949 | Benzodiazepine Interpretation | 69050-3 |
| 624241 | Buprenorphine | 93494-3 |
| 624242 | Norbuprenorphine | 82371-6 |
| 624243 | Norbuprenorphine glucuronide | 89305-7 |
| 624244 | Opioid Interpretation | 69050-3 |